ArticleAAPS PharmSciTech2014
In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.
Article in AAPS PharmSciTech, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Detection of Micrometer-Sized Virus Aerosols by Using a Real-Time Bioaerosol Monitoring System.Biosensors · 2024Article
- Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Progress on Thin Film Freezing Technology for Dry Powder Inhalation Formulations.Pharmaceutics · 2022Review
- Manufacturing Stable Bacteriophage Powders by Including Buffer System in Formulations and Using Thin Film Freeze-drying Technology.Pharmaceutical research · 2021Article
- Pulmonary Drug Delivery of Antimicrobials and Anticancer Drugs Using Solid Dispersions.Pharmaceutics · 2021Review
- Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration.AAPS PharmSciTech · 2021Article
- Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model.Frontiers in pharmacology · 2021Article
- Bioavailability Improvement of Carbamazepine via Oral Administration of Modified-Release Amorphous Solid Dispersions in Rats.Pharmaceutics · 2020Article
- Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing.Pharmaceutics · 2020Article
- Co-Amorphization of Kanamycin with Amino Acids Improves Aerosolization.Pharmaceutics · 2020Article
- Supercritical CO₂-Assisted Spray Drying of Strawberry-Like Gold-Coated Magnetite Nanocomposites in Chitosan Powders for Inhalation.Materials (Basel, Switzerland) · 2017Article
- Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems.Journal of drug delivery · 2016Review
- Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug delivery.AAPS PharmSciTech · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, inhaled immunosuppressive agents have attracted increasing attention for maintenance therapy following lung transplantation. The rationale for this delivery approach includes a more targeted and localized delivery to the diseased site with reduced systemic exposure, potentially leading to decreased adverse side effects. In this study, the in vitro and in vivo performance of an amorphous formulation prepared by thin film freezing (TFF) and a crystalline micronized formulation produced by milling was compared for tacrolimus (TAC). Despite the relatively large geometric size, the TFF-processed formulation was capable of achieving deep lung delivery due to its low-density, highly porous, and brittle characteristics. When emitted from a Miat® monodose inhaler, TFF-processed TAC formulations exhibited a fine particle fraction (FPF) of 83.3% and a mass median aerodynamic diameter (MMAD) of 2.26 μm. Single-dose 24-h pharmacokinetic studies in rats demonstrated that the TAC formulation prepared by TFF exhibited higher pulmonary bioavailability with a prolonged retention time in the lung, possibly due to decreased clearance (e.g., macrophage phagocytosis), compared to the micronized TAC formulation. Additionally, TFF formulation generated a lower systemic TAC concentration with smaller variability than the micronized formulation following inhalation, potentially leading to reduced side effects related to the drug in systemic circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.